PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma.

Jiazhuo WuCunzhen ShiHongwen LiWenting SongShuo HuangJianxiang ZhangWencai LiZhaoming LiMing-Zhi Zhang

Published in: BMC medicine (2023)

In summary, we found that PARPi exerted an anti-tumor effect via LMO2 and synergized with cisplatin in NKTCL, which provides the theoretical basis for the clinical application of PARPi.

Keyphrases

dna damage
dna repair